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Abstract
Background Hypertrophic cardiomyopathy (HCM) is
the most prevalent monogenic heart disease, com-
monly caused by truncating variants in the MYBPC3
gene. HCM is an important cause of sudden cardiac
death; however, overall prognosis is good and pene-
trance in genotype-positive individuals is incomplete.
The underlying mechanisms are poorly understood
and risk stratification remains limited.
Aim To create a nationwide cohort of carriers of trun-
catingMYBPC3 variants for identification of predictive
biomarkers for HCM development and progression.
Methods In the multicentre, observational BIO FOr
CARe (Identification of BIOmarkers of hypertrophic
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cardiomyopathy development and progression in
Dutch MYBPC3 FOunder variant CARriers) cohort,
carriers of the c.2373dupG, c.2827C>T,
c.2864_2865delCT and c.3776delA MYBPC3 variants
are included and prospectively undergo longitudinal
blood collection. Clinical data are collected from first
presentation onwards. The primary outcome con-
stitutes a composite endpoint of HCM progression
(maximum wall thickness ≥20mm, septal reduction
therapy, heart failure occurrence, sustained ventricu-
lar arrhythmia and sudden cardiac death).
Results So far, 250 subjects (median age 54.9 years
(interquartile range 43.3, 66.6), 54.8%male) have been
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included. HCM was diagnosed in 169 subjects and
dilated cardiomyopathy in 4. The primary outcome
was met in 115 subjects. Blood samples were collected
from 131 subjects.
Conclusion BIO FOr CARe is a genetically homoge-
neous, phenotypically heterogeneous cohort incorpo-
rating a clinical data registry and longitudinal blood
collection. This provides a unique opportunity to
study biomarkers for HCM development and progno-
sis. The established infrastructure can be extended to
study other genetic variants. Other centres are invited
to join our consortium.
Keywords Hypertrophic cardiomyopathy · MYBPC3 ·
Biomarkers · Prognosis
Introduction
Hypertrophic cardiomyopathy (HCM) is characterised
by hypertrophy of the ventricular wall not explained
by abnormal loading conditions [1]. HCM is an impor-
tant cause of sudden cardiac death (SCD) [2] and may
also lead to end-stage heart failure and left ventric-
ular outflow tract (LVOT) obstruction [3]. The preva-
lence of HCM has historically been estimated at 1:500
[4], making it the most common Mendelian heart dis-
ease, with more recent estimates as high as 1:200 [5].
HCM is typically inherited as an autosomal dominant
disease and a likely pathogenic/pathogenic variant is
found in approximately 50% of patients [6, 7]. The
most commonly affected gene is MYBPC3, which en-
codes cardiac myosin-binding protein C (cMyBP-C),
an important regulator of cardiomyocyte contraction
[3].
Despite the association with life-threatening ar-
rhythmia and end-stage heart failure, clinical severity
in HCM is highly variable, with low overall mortality
[8] and incomplete, age-dependent penetrance in car-
riers of pathogenic variants (G+) [9]. This highlights
the need for risk stratification. Current guidelines
advocate the use of the HCM Risk-SCD calculator
to identify patients who may benefit from a prophy-
lactic implantable cardioverter-defibrillator [1, 10].
However, prediction of SCD remains imperfect [11]
and risk-prediction models of other aspects of HCM
have not yet been established. Furthermore, underly-
ing mechanisms contributing to disease progression,
such as environmental and additional (epi)genetic
factors, are still unclear.
Similarly, prediction of penetrance in G+ phe-
notype-negative (LVH-) individuals is limited. Risk
factors and biomarkers found in exploratory stud-
ies, including electrocardiographic abnormalities
and impaired diastolic function on echocardiogra-
phy [12–14], have not yet been validated in large,
prospective cohorts. Without such data, these in-
dividuals undergo frequent cardiological screenings
with a major impact on the health care system and
costs.
The Dutch HCM population is relatively genetically
homogeneous, with three MYBPC3 founder variants
(c.2373dupG (p.Trp792fs), c.2827C>T (p.Arg943Ter)
and c.2864_2865delCT (p.Pro955fs), each inherited
from a distant common ancestor) accounting for up
to 35% of Dutch HCM cases [15]. Another truncat-
ing MYBPC3 variant, c.3776delA (p.Gln1259fs), has
been identified in multiple independently presenting
HCM patients. These genetic variants result in trun-
cated mRNA, absence of truncated cMyBP-C protein
and a reduction of functional cMyBP-C (haploinsuf-
ficiency) [16], which impairs cardiomyocyte function
[17], and have been shown to have a similar prog-
nostic impact [18]. Together, they provide a unique
opportunity to study effect modifiers free from con-
founding resulting from distinct genotypes.
In the BIO FOr CARe (Identification of BIOmarkers
of hypertrophic cardiomyopathy development and
progression in Dutch MYBPC3 FOunder variant
CARriers) study we aim to investigate predictive fac-
tors and effect modifiers for penetrance and progres-
sion of HCM in the genetically homogeneous group of
Dutch carriers of truncating MYBPC3 variants. Here
we report the design and current status of this cohort
and discuss ongoing and future studies.
Methods
Subject inclusion
Subjects are included as part of the ongoing prospec-
tive, multicentre, longitudinal, observational BIO FOr
CARe cohort, embedded in the CVON DOSIS (Car-
diovascular Research Netherlands—Determinants Of
Susceptibility In inherited cardiomyopathy: towards
novel therapeutic approacheS) consortium [19]. The
design of this study is illustrated in Fig. 1. In short,
clinical data from each subject’s first cardiomyopa-
thy-related presentation onwards (due to symptoms
or coincidental findings prompting echocardiography
and/or cardiac magnetic resonance imaging (MRI), or
screening for familial disease) are retrospectively col-
lected in a registry and subjects prospectively undergo
blood collection.
Subject inclusion started at the University Medi-
cal Centre Utrecht in January 2017, at the University
Medical Centre Groningen in December 2017, at the
Amsterdam University Medical Centre in January 2019
and is expected to commence shortly at the Erasmus
Medical Centre in Rotterdam. G+ index patients (first
family member to undergo genetic testing) and fam-
ily members are identified through the genome di-
agnostics laboratories of each of these centres and
screened for eligibility. Inclusion criteria are carri-
ership of c.2373dupG, c.2827C>T, c.2864_2865delCT
or c.3776delA variant in MYBPC3 (reference sequence
NM_000256.3) and age ≥18 years. Patients with prior
heart transplantation are included in the clinical data
registry, but are excluded from blood collection.
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Fig. 1 Schematic overview of the study design. The BIO
FOr CARe (Identification of BIOmarkers of hypertrophic car-
diomyopathy development and progression in DutchMYBPC3
FOunder variant CARriers) study comprises an observational
cohort of Dutch carriers of the c.2373dupG (p.Trp792fs),
c.2827C>T (p.Arg943Ter), c.2864_2865delCT (p.Pro955fs)
and c.3776delA (p.Gln1259fs) variants in the MYBPC3 gene.
These variants are predicted to result in truncated mRNA with
absence of truncated protein leading to haploinsufficiency.
Subjects across the phenotypic spectrum associated with
these variants are prospectively included for blood collection
every 2 years and followed up over time. Clinical data are
retrospectively collected from the first presentation onwards
in a clinical registry to assess potential clinical predictors of
disease penetrance and progression. HCM hypertrophic car-
diomyopathy
This study is performed in accordance with the
Helsinki declaration and was approved by the Med-
ical Ethics Committee of the UMC Utrecht. Informed
consent is obtained from all subjects.
Study outcome
The primary outcome of this study is a composite end-
point representing disease progression, consisting of
(1) maximum wall thickness (MWT) ≥20mm, (2) oc-
currence of heart failure (congestive heart failure or
left ventricular ejection fraction <50%), (3) LVOT ob-
struction (LVOT gradient ≥30mmHg with symptoms
or ≥50mmHg regardless of symptoms) or (4) malig-
nant arrhythmia (sustained ventricular tachycardia,
ventricular fibrillation, appropriate implantable car-
dioverter-defibrillator intervention, cardiac arrest or
SCD).
HCM is diagnosed according to the European So-
ciety of Cardiology criteria, summarised as a MWT of
≥15mm in probands or ≥13mm in first-degree fam-
ily members, not proportional to abnormal loading
conditions [1]. Dilated cardiomyopathy (DCM), which
may likewise occur in carriers of MYBPC3 variants, is
diagnosed in accordance with the revised definition
of the European Society of Cardiology myocardial and
pericardial diseases working group [20]. Subjects ful-
filling DCM criteria are carefully evaluated for signs of
prior HCM (prior or persisting hypertrophy fulfilling
diagnostic criteria for HCM).
Study data
Study data are collected from electronic health records
using a REDCap (Research Electronic Data Capture,
Vanderbilt University, Nashville, TN, USA) tool hosted
by the Netherlands Heart Institute. Baseline data
include patient demographics, genetic analyses, fam-
ily history, medical history, laboratory results, and
conventional electrocardiography, ambulatory Holter
monitoring, exercise test, echocardiography and car-
diac MRI parameters. A comprehensive list of clinical
variables is provided in the Electronic Supplementary
Material (Table S1). The full data dictionary is avail-
able upon request. Clinical management and follow-
up intervals remain at the discretion of the subject’s
cardiologist.
Statistical analysis and sample size calculation
All analyses were conducted in R version 4.0.0 (R De-
velopment Core Team, 2017) using RStudio ver-
sion 1.1.414 (RStudio Team, 2015). Dichotomous
variables are presented as counts with percent-
ages and were analysed using two-sided Fisher’s
exact test. Continuous variables are presented as
means± standard deviations or medians with in-
terquartile ranges according to their distribution and
analysed using unpaired t- or Mann-Whitney U tests
accordingly.
According to the ‘one in ten’ rule of thumb for re-
gression analyses, 30 subjects would have to fulfil the
primary outcome to assess one biomarker and correct
for two variables (age and sex). Assuming 40% of en-
rolled subjects to be G+LVH- at baseline, 75% of these
G+ LVH- subjects to develop a phenotype throughout
life and 10% of those developing a phenotype to ful-
fil the primary outcome, a total of 1000 subjects are
required to enrol in the study.
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Blood collection
Standardised blood collection is performed to study
potential biomarkers for HCM development and pro-
gression. Using 23G winged blood collection sets,
venous blood samples are collected and processed
within 45min to obtain 4× 500µl plasma from cit-
rate tubes, 6× 500µl plasma and a dried (whole) blood
spot card from lithium-heparin tubes, 6× 500µl serum
and a whole-blood PAXgene RNA tube (PreAnalytiX
GmbH, Hombrechtikon, Switzerland). The laboratory
protocol is provided in the Electronic Supplementary
Material (Fig. S1).
Preliminary results
A flowchart outlining subject inclusion and follow-up
is presented in Fig. 2. A total of 250G+ individuals
were included in the study up to 1 January 2020. In
232 subjects the diagnosis could be ascertained. HCM
was diagnosed in 169 subjects and DCMwithout prior
diagnosis of HCM in 4 subjects. The remaining 59 sub-
jects were G+ LVH- at the time of inclusion. Baseline
characteristics are presented in Tab. 1. A male pre-
dominance (66%) was observed among index patients,
similar to previous studies [21, 22]. To date, blood
samples have been obtained from 131 subjects. As
Fig. 2 Flowchart show-
ing the results of subject
screening, as well as data
on inclusion and blood col-
lection. The reasons for
exclusion are noted on the
right for each stage. Re-
quested local denotes sub-
jects who requested blood
collection in local cardio-
logical centres. HTx heart
transplantation
Screened MYBPC3 c.2373dupG, 
c.2827C>T, c.2864_2865delCT 
and c.3776delA carriers
n = 902 Deceased (n = 64)
HTx (n = 4)
Age < 18 years (n = 40)







To be invited (n = 193)
No reply (n = 245)
No consent (n = 81)
Screening failure (n = 1)
To be contacted (n = 98)
Requested local (n = 9)


















shown in the Electronic Supplementary Material (Ta-
ble S2), the baseline characteristics of subjects who
have undergone blood collection and those who have
not are similar.
Ongoing and future projects
Currently, two biomarker discovery studies are on-
going in the BIO FOr CARe cohort, both utilising
metabolomics approaches. Previous studies have
indicated a perturbed energy metabolism in HCM
with an increased adenosine triphosphate utilisation
and decreased energetic efficiency [16, 23]. Acyl-
carnitines are forms of fatty acids transported into
mitochondria for energy production [24]. Changes
in acylcarnitine concentrations have been shown to
reflect a shift away from the fatty acid oxidation that
is normally predominant in cardiac tissue, towards
glucose utilisation in a MYBPC3 HCM mouse model
treated with perhexiline (which blocks transportation
of fatty acids into mitochondria) [25]. This shift to in-
creased glucose utilisation is more generally observed
in heart failure [26], in which increased levels of long-
chain acylcarnitines have been associated with worse
prognosis [27].
In the BIO FOr CARe study, acylcarnitines were de-
termined using targeted metabolomics in 121 plasma
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Table 1 Subject characteristics
Overall Index patient Family member p-value
(n= 250) (n= 97) (n= 153)
Demographics
Age at inclusion (years) 54.9 [43.3, 66.6] 55.5 [47.3, 67.2] 53.7 [40.5, 64.5] 0.183
Male sex 137 (54.8) 64 (66.0) 73 (47.7) 0.007
Body surface area (m2) 1.96 [1.83, 2.13] 1.95 [1.85, 2.19] 1.96 [1.82, 2.10] 0.448
Genetics
c.2373dupG 185 (74.0) 69 (71.1) 116 (75.8) 0.500
c.2827C>T 30 (12.0) 14 (14.4) 16 (10.5) 0.425
c.2864_2865delCT 15 (6.0) 5 (5.2) 10 (6.5) 0.788
MYBPC3 variant
c.3776delA 20 (8.0) 9 (9.3) 11 (7.2) 0.634
Patient history
Syncope 28 (11.8) 15 (16.1) 13 (9.0) 0.103
I/II 144 (93.5) 52 (88.1) 92 (96.8) 0.045NYHA class
III/IV 10 (6.5) 7 (11.9) 3 (3.2)
Any first-degree family member 86 (36.0) 0.489Family history of sudden cardiac death




Non-sustained ventricular tachycardia 102 (57.0) 51 (65.4) 51 (50.5) 0.050
Imaging
Maximum wall thickness (mm) 16 [12, 20] 19 [17, 23] 13 [10, 17] <0.001
Maximum LV outflow tract gradient
(mmHg)
6 [4, 10] 8 [5, 15] 5 [4, 7] 0.003
LV end-diastolic diameter (mm) 46 [40, 50] 45 [40, 49] 46 [41, 50] 0.438
LV ejection fraction (%) 60 [55, 62] 60 [52, 62] 60 [55, 63] 0.232
Normal 69 (59.5) 13 (36.1) 56 (70.0) <0.001
Impaired relaxation 29 (25.0) 10 (27.8) 19 (23.8)
Pseudonormalisation 11 (9.5) 9 (25.0) 2 (2.5)
LV diastolic dysfunction
Restrictive 7 (6.0) 4 (11.1) 3 (3.8)
LA diameter (mm) 41 [36, 46] 42 [37, 46] 39 [36, 46] 0.533
Outcomes at inclusion
Phenotype-negative 59 (25.4) 3 (3.2)a 56 (40.6) <0.001
HCM 13–14mm 18 (7.8) 1 (1.1) 17 (12.3)
HCM≥15mm 151 (65.1) 88 (93.6) 63 (45.7)
Phenotype
DCM 4 (1.7) 2 (2.1) 2 (1.4)
Composite endpoint 115 (50.2) 71 (78.0) 44 (31.7) <0.001
Maximum wall thickness ≥20mm 88 (39.8) 58 (65.9) 30 (22.4) <0.001
Septal reduction therapy 17 (7.8) 14 (16.1) 3 (2.3) <0.001
Malignant ventricular arrhythmia 21 (9.3) 14 (15.4) 7 (5.1) 0.011
Heart failure 47 (22.0) 30 (34.9) 17 (13.2) <0.001
Congestive heart failure 28 (13.6) 17 (21.8) 11 (8.5) 0.011
Primary outcome
Systolic heart failure 33 (16.0) 20 (26.3) 13 (9.9) 0.003
NYHA New York Heart Association, ESC European Society of Cardiology, SCD sudden cardiac death, LV left ventricular, LA left atrial, HCM hypertrophic cardiomy-
opathy, DCM dilated cardiomyopathy
Continuous data are shown as means± standard deviation for normally distributed variables or median [interquartile range] for non-normally distributed vari-
ables. Dichotomous and categorical data are shown as counts (% of valid). p-values <0.05 are depicted in bold
aIncidental finding in one subject and genetic testing prompted by a sudden cardiac death of a family member in two subjects
samples, together with 27 samples collected prior to
genetic testing as part of the UNRAVEL biobank [28],
including 12 genotype-negative relatives not eligi-
ble for inclusion in BIO FOr CARe. To further study
changes in the metabolome associated with HCM, un-
targeted metabolomics using a previously published
direct-infusion high-resolution mass spectrometry
platform [29] was performed in a nested case-control
study, consisting of 30 subjects with a severe phe-
notype and 30 age- and sex-matched subjects with
a mild or no phenotype, as well as 10 age- and sex-
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matched genotype-negative family members from the
UNRAVEL biobank.
Additionally, an exploratory proteomics study using
the Olink Cardiovascular III multiplex immunoassay
(for more information, visit: https://www.olink.com/
products/cvd-iii-panel/) is being designed. Further-
more, the BIO FOr CARe infrastructure is currently
being used for observational cohort studies involving
other HCM genotypes and for gene-expression studies
in induced pluripotent stem-cell-derived cardiomy-
ocytes, and will be used for potential future genome-
wide association studies/polygenic risk score analy-
ses.
Discussion
The BIO FOr CARe cohort offers a unique opportunity
to investigate predictive factors and effect modifiers
for penetrance and progression of HCM. Currently,
250 carriers of truncating MYBPC3 variants across the
phenotypic spectrum have been included. Blood sam-
ples have been obtained from 131 subjects and several
biomarker discovery studies are currently underway.
Standardisation of blood collection allows for fu-
ture biomarker studies requiring plasma, serum or
RNA. By repeating blood collection at subsequent
time points, changes in biomarker concentrations can
be validated over time and across progressive stages of
the phenotype. The current biomarker studies are still
limited to a cross-sectional design. However, longitu-
dinal assessment of biomarkers will become possible
over time, as disease onset and progressionmay occur
in carriers during follow-up.
The prognostic utility of biomarkers in HCM is
also being studied in several other studies, such as
the HCMR—Novel Markers of Prognosis in Hyper-
trophic Cardiomyopathy (HCMR) study (Clinical-
Trials.gov Identifier: NCT01915615) [30], the Pre-
dictive Factors and Consequences of Myocardial
Fibrosis in Hypertrophic Cardiomyopathy (HCM)
study (NCT02922517), the Cardiac Biomarkers in
Pediatric Cardiomyopathy (PCM Biomarkers) study
(NCT01873976), and the An Integrative-‘Omics’ Study
of Cardiomyopathy Patients for Diagnosis and Prog-
nosis in China (AOCC) study (NCT03076580). Our
study distinguishes itself by its genotype-driven study
population, including carriers of pathogenic variants
regardless of their phenotype, and its longitudinal
design. The inclusion of G+ LVH- individuals is made
possible by the widespread availability of genetic
screening to family members (covered by the national
basic healthcare plan), which has led to the identi-
fication of many G+LVH-family members [7]. This
provides a unique opportunity to study biomarkers
and their prognostic utility at subsequent stages of
disease progression. Furthermore, the high preva-
lence of MYBPC3 founder variants in the Dutch HCM
population allows analyses free from confounding
resulting from genetic heterogeneity [15].
Additionally, the ancillary REDCap registry offers
a user-friendly, sustainable platform for clinical data
collection using standardised definitions. Similar to
the Netherlands Arrhythmogenic Cardiomyopathy
Registry [31], this may serve as a foundation for fu-
ture observational studies, involving carriers of other
variants and other genetic cardiomyopathies. A wide
range of data is collected from the subject’s first pre-
sentation onwards, enabling both cross-sectional and
longitudinal studies as well as hypothesis-driven and
hypothesis-generating approaches. New variables can
easily be added to accommodate studies focussing on
specific disease aspects.
Both data and samples are available to external
researchers through submission of an application to
our data access board, which consists of investiga-
tors from each participating centre. So far, inclusions
have focussed on the genetically homogeneous cohort
of pathogenic truncating MYBPC3 variants. Although
the prognosis of HCM patients carrying founder vari-
ants inMYBPC3 has been shown to be similar to other
G+HCM [18, 21], findings in our current cohort will
have to be validated in the general HCM population.
An amendment to the BIO FOr CARe protocol to in-
clude all HCM genotypes has recently been accepted.
External validation may be performed in large multi-
national cohorts such as the HCMR study [30]. Poten-
zial effect modifiers may be further studied in my-
ocardial samples collected from septal myectomies or
during heart transplantation.
A limitation of the current study design is the risk
of referral bias, as blood collection is limited to aca-
demic hospitals, which may hinder patients who are
under cardiological follow-up elsewhere and do not
live nearby. This likely contributed to the higher than
anticipated number of subjects fulfilling the primary
outcome at baseline (50%). Extending blood collec-
tion to regional hospitals would ameliorate the po-
tential bias. A second limitation is that clinical data
were not collected prospectively, resulting in missing
data. A further limitation to this study is that event
rates are low in HCM [8]. As a result, a large sam-
ple size and long follow-up duration are required for
prospective and longitudinal studies, for which em-
bedding in a sustainable infrastructure and long-term
funding are essential. Finally, as the subjects in this
study were ascertained as index patients or through
their relatedness to one, results may not be general-
isable to carriers of MYBPC3 variants in the general
population. Instead, population-based studies are re-
quired to investigate the prognosis of carriers in the
general population.
Conclusion
The BIO FOr CARe cohort incorporates a clinical data
registry and standardised prospective blood sample
collection, offering a unique opportunity to investi-
gate factors affecting development and progression of
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HCM in carriers of truncating founder MYBPC3 vari-
ants. The cohort comprises patients across the phe-
notypic spectrum, allowing cross-sectional biomarker
studies, of which several are under way. Longitudinal
collection of blood samples and clinical data allows
prospective and longitudinal assessment of biomark-
ers at progressive stages of HCM. The established
collaborations and infrastructure can be extended to
study other genotypes and different genetic cardiomy-
opathies. Other centres are invited to join our consor-
tium.
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